This Comprehensive Cancer Center is based at the University of Alabama (UAB) and the UAB Medical Center. The Center has been funded by NCI continuously since 1971 and currently has 294 faculty members, $86.01 million of total annual research support, and 138,000 square feet OF Cancer Center controlled space. The Cancer Center administratively functions as a University-wide Interdisciplinary Research Center (matrix organization) with involvement of faculty and resources from 36 departments in 6 Schools of the institution. The Center evaluates 3,000 new cancer cases annually and has 100 cancer beds in the University of Alabama Hospital with extensive modern ambulatory facilities in the Kirklin Clinic. In 1998, the Center had a clinical trials effort exceeding 3,700 registrations including 365 patients on the therapeutic intervention trials with a heavy emphasis on investigator initiated, interdisciplinary/translational studies. Four NCI-funded mega-trials in prevention or screening had over 3,000 registrations with a heavy emphasis on minority and underserved populations. The Center is organized into nine interdisciplinary research programs: Immunology, Structural Biology, Molecular Genetics, Virology, Experimental Therapeutics, Women's Cancers, Neuro-Oncology, Cancer Control & Population Science, and Cancer Chemoprevention. It currently has 14 shared facilities including: Biostatistics, Clinical Studies, Fermentation, High Resolution Imaging, Mass Spectroscopy, Media Preparation, Molecular NMR, Oligonucleotide Synthesis, Pathogen-Free Rodent, Peptide Analysis & Synthesis, Radiolabeling, Tissue Procurement, Transgenic Animal/Embryonic Stem Cell, and X-ray Crystallography. We have requested support for 3 new shared facilities including: Immunopathology Gene Expression, Recruitment & Retention, Gene Therapy & Vaccine Vector Production. In addition, the Center has an active developmental effort with annual pilot research project funding and funding for support of new investigator recruitment and/or start up. A formal planning process involving internal committees and external consultants provides advice to the senior leadership of the Center. The Center has strong support from the University and a productive record of successful competitive grant support and scientific publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013148-30
Application #
6362510
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1985-07-01
Project End
2005-02-28
Budget Start
2001-03-07
Budget End
2002-02-28
Support Year
30
Fiscal Year
2001
Total Cost
$4,541,851
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Geng, Mengxin; Austin, Frank; Shin, Ronald et al. (2018) Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Appl Environ Microbiol 84:
Powell, T Clark; Dilley, Sarah E; Bae, Sejong et al. (2018) The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. J Low Genit Tract Dis 22:269-273
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230

Showing the most recent 10 out of 747 publications